Pharma BD Deal Intelligence
Takeda's $6B acquisition of Nimbus Lakshmi for a TYK2 inhibitor targeting autoimmune diseases — a bet on best-in-class oral efficacy in a crowded immunology field. The deal gave Takeda a high-value pipeline asset, though clinical and commercial validation still lies ahead.
Takeda acquired Nimbus Lakshmi for $6B for TYK2 inhibitor for autoimmune diseases.
Takeda will acquire all shares of Nimbus Lakshmi for $4 billion upfront plus up to $2 billion in sales-based milestones, gaining NDI-034858 (TAK-279), an oral…
Phase 3 Latitude PsO 3001/3002: sPGA 0/1 71.4%/69.2% vs apremilast 32.1%/29.7% and placebo 10.7%/12.6% at wk16; PASI 90 61.3%/51.9%. On track to submit NDA to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Takeda acquired Nimbus Lakshmi for $6B for TYK2 inhibitor for autoimmune diseases.
7.5M US cases/yr · $22.0B Global Psoriasis Market (2024)
Plaque psoriasis is a chronic autoimmune skin condition affecting ~3% of the US population. Treatment has been transformed by biologics (IL-17, IL-23, TNF inhibitors) and oral TYK2 inhibitors. TAK-279 is a potentially best-in-class allosteric TYK2 inhibitor differentiated from BMS Sotyktu.
TAK-279 (formerly NDI-034858) is an allosteric TYK2 inhibitor like Sotyktu (deucravacitinib) but with potentially improved potency and broader autoimmune applications. Phase 2b met PASI-75 in psoriasis. Expanding into psoriatic arthritis, IBD, and other I&I indications.
Takeda announced acquisition of Nimbus Lakshmi for TYK2 inhibitor NDI-034858 (TAK-279) for $4B upfront plus $2B in sales milestones.
FTC clearance obtained; Takeda completed acquisition of Nimbus Lakshmi subsidiary, triggering $4B upfront payment.
TAK-279 showed PASI 75 rates of 44-68% vs 6% placebo in moderate-to-severe plaque psoriasis Phase 2b trial.
Zasocitinib met all co-primary and 44 ranked secondary endpoints in two pivotal Phase 3 psoriasis trials. Over 50% achieved PASI 90 at week 16.
Takeda reported full Phase 3 plaque-psoriasis results for zasocitinib (TAK-279): sPGA 0/1 of 71.4%/69.2% at week 16 vs ~30% apremilast and ~11-13% placebo; PASI 90 61.3%/51.9%. No new safety signals. On track to begin NDA submission with FDA and other regulators starting fiscal year 2026. Thesis validated: lead asset cleared Phase 3 and is heading to filing.
See timeline for full assessment. Assessment of Takeda Pharmaceutical Co.'s $6B acquisition of Nimbus Lakshmi and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi (this deal) | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2022 deals · Takeda Pharmaceutical Company Ltd. deals · Dermatology deals